Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis

Proliferation tracing reveals regional hepatocyte generation in liver homeostasis and repair

(2021) Lingjuan He et al.   SCIENCE

T Lymphocyte-Mediated Liver Immunopathology of Schistosomiasis

(2020) Bing Zheng et al.   Frontiers in Immunology

Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics

(2020) Qingke Li et al.   CELL

Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists

(2020) Xin Zhang et al.   MOLECULAR CELL

Endothelin receptors promote schistosomiasis-induced hepatic fibrosis via splenic B cells

(2020) Hongyan Kong et al.   PLoS Pathogens

AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis

(2020) Hongjiao Xu et al.   Nature Communications

Mitophagy regulates mitochondrial network signaling, oxidative stress, and apoptosis during myoblast differentiation

(2019) Brittany L. Baechler et al.   Autophagy

Praziquantel Ameliorates CCl 4 ‐induced Liver Fibrosis in Mice by Inhibiting TGF‐β/Smad Signalling via Upregulating Smad7 in Hepatic Stellate Cells

(2019) Jinfeng Liu et al.   BRITISH JOURNAL OF PHARMACOLOGY

Dual glucagon‐like peptide‐1 receptor/glucagon receptor agonist SAR425899 improves beta‐cell function in type 2 diabetes

(2019) Roberto Visentin et al.   DIABETES OBESITY & METABOLISM

Genetically Encoding Fluorosulfate-l-tyrosine To React with Lysine, Histidine, and Tyrosine via SuFEx in Proteins in Vivo

(2018) Nanxi Wang et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study

(2018) Philip Ambery et al.   LANCET

Liver fibrosis: Direct antifibrotic agents and targeted therapies

(2018) Detlef Schuppan et al.   MATRIX BIOLOGY

Exendin‐4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant

(2018) Michelle Khai Khun Yap et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Rapeseed Protein-Derived Antioxidant Peptide RAP Ameliorates Nonalcoholic Steatohepatitis and Related Metabolic Disorders in Mice

(2018) Qian Zhao et al.   MOLECULAR PHARMACEUTICS

Host Regulators of Liver Fibrosis During Human Schistosomiasis

(2018) Severin Donald Kamdem et al.   Frontiers in Immunology

A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice

(2017) M. Pilar Valdecantos et al.   HEPATOLOGY

Mechanisms of hepatic stellate cell activation

(2017) Takuma Tsuchida et al.   Nature Reviews Gastroenterology & Hepatology

The liver-enriched lnc-LFAR1 promotes liver fibrosis by activating TGFβ and Notch pathways

(2017) Kun Zhang et al.   Nature Communications

Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies

(2017) Fernanda Cristina de Mesquita et al.   Scientific Reports

Dose-dependent effects of alpha-naphthylisothiocyanate disconnect biliary fibrosis from hepatocellular necrosis

(2016) Nikita Joshi et al.   JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY

Hepcidin inhibits Smad3 phosphorylation in hepatic stellate cells by impeding ferroportin-mediated regulation of Akt

(2016) Chang Yeob Han et al.   Nature Communications

Experimental models of liver fibrosis

(2015) Sara Crespo Yanguas et al.   ARCHIVES OF TOXICOLOGY

Schistosome-induced cholangiocyte proliferation and osteopontin secretion correlate with fibrosis and portal hypertension in human and murine schistosomiasis mansoni

(2015) T. A. Pereira et al.   CLINICAL SCIENCE

Hepatic inflammation and fibrosis: Functional links and key pathways

(2015) Ekihiro Seki et al.   HEPATOLOGY

The Hippo pathway effector YAP controls mouse hepatic stellate cell activation

(2015) Inge Mannaerts et al.   JOURNAL OF HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease

(2013) H. Kahal et al.   CLINICAL ENDOCRINOLOGY

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

A Liver Full of JNK: Signaling in Regulation of Cell Function and Disease Pathogenesis, and Clinical Approaches

(2012) Ekihiro Seki et al.   GASTROENTEROLOGY

Deactivation of Hepatic Stellate Cells During Liver Fibrosis Resolution in Mice

(2012) Juliane S. Troeger et al.   GASTROENTEROLOGY

Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis

(2012) T. Kisseleva et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Pathogenesis of Liver Fibrosis

(2011) Virginia Hernandez-Gea et al.   Annual Review of Pathology-Mechanisms of Disease

Partial bile duct ligation in mice: A novel model of acute cholestasis

(2010) Stefan Heinrich et al.   SURGERY

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

(2009) A. Pocai et al.   DIABETES

Experimental mouse models for hepatocellular carcinoma research

(2009) Femke Heindryckx et al.   INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

(2009) Jonathan W Day et al.   Nature Chemical Biology

Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain

(2008) Steffen Runge et al.   JOURNAL OF BIOLOGICAL CHEMISTRY